The first classification step is identity control. TB-500 and full-length thymosin beta-4/Tβ4 should not be used as interchangeable names unless the product documentation proves it.

• FDA-described TB-500 is thymosin beta-4 fragment LKKTETQ, a heptapeptide fragment.
• Full-length thymosin beta-4/Tβ4/timbetasin is a naturally occurring 43-amino-acid actin-sequestering peptide found in many tissues and wound contexts.
• Vendor-labeled TB-500 may refer to LKKTETQ fragment, N-acetylated fragment, full-length Tβ4, salt forms, a blend component, or inaccurately labeled material.
• The key identity issue is sequence: LKKTETQ and full-length Tβ4 have different residue profiles, likely different PK, and different evidence boundaries.
• COA review to distinguish exact makeup should include full HPLC/UPLC purity, high-resolution mass-spec identity, expected molecular mass, sequence confirmation when possible, endotoxin testing, sterility testing, and blend-specific content where applicable.
• FDA-described TB-500/LKKTETQ fragment, full-length thymosin beta-4, and unresolved vendor-labeled TB-500 are three different things. These are not interchangeable for sequence, mechanism, route evidence, or oxidation assumptions.

The repair rationale for thymosin beta-4-family products centers on actin/cell-migration biology, but the strength and meaning of that claim depends on the exact identity.

• Full-length Tβ4: sequesters G-actin and helps regulate cytoskeletal organization; This is central to cell movement and repair-cell migration.
• TB-500/LKKTETQ: an active-region fragment associated with the actin-binding region; Do not assume it reproduces full-length Tβ4 distribution, half-life, or all biological functions.
• Cell migration: epithelial cells, endothelial cells, keratinocytes, and other repair cells must migrate across damaged tissue; Tβ4-family biology is repeatedly linked to this process.
• Angiogenesis: repair requires blood-vessel support; This may help explain wound-healing signals but also raises cancer and abnormal-angiogenesis caution.
• Anti-inflammatory/anti-fibrotic effects: strongest as full-length Tβ4-family research context, not as proof for every TB-500-labeled product.
• Product-specific uncertainty: fragment, full-length, recombinant, salt, and blend products can differ in receptor/signaling context, immunogenicity, stability, and PK.
• Full-length Tβ4 biology includes actin-binding, cell migration, angiogenesis, and wound-repair signaling. The LKKTETQ fragment may capture only part of this biology, so mechanism claims hold only when they match identity. The mechanism here is a plausibility map, not proof of a clinical outcome.

• Identity distinction: FDA identifies TB-500 as thymosin beta-4 fragment LKKTETQ in its compounding safety-risk discussion; That is not the same as full-length 43-amino-acid Tβ4.
• Full-length Tβ4 research: corneal epithelial healing, dry eye, neurotrophic keratopathy, wound repair, inflammatory modulation, and cardiac contexts are mostly Tβ4-family/full-length evidence, not generic TB-500 validation.
• Human safety/PK research: human Phase 1 work with recombinant human thymosin beta-4 reported tolerability and collected pharmacokinetic and anti-drug-antibody data; This supports continued research but does not validate unregulated TB-500 products.
• Fragment/TB-500 gap: FDA states it has not identified human exposure data for drug products containing thymosin beta-4 fragment LKKTETQ/TB-500 in the compounding safety-risk context.
• Sports-medicine translation: animal, equine, and anti-doping detection literature contribute to TB-500’s reputation in injury recovery; These data do not establish an approved human injury-repair regimen.
• Full-length Tβ4 has more topical/ophthalmic and wound-related investigational literature than the short TB-500 fragment. Community injury-repair reports do not establish efficacy for either product class. These are separate tiers of evidence: preclinical data, regional human reports, approved-product evidence, and community anecdotes.

Below you'll find reported clinical-label, research, and community-use dosing contexts where available. It's educational reference only, not dosing instructions for you.

• Protocol 1: Intensive Repair Protocol [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC) or Intramuscular (IM); Dose: Weekly Dose: 5.0 mg – 10.0 mg; Frequency: Split into 2 or 3 injections; Duration: 4 to 6 weeks; Max: 15.0 mg (per week, acute); Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written; Identity note: rows do not establish equivalence between TB-500 fragment, full-length Tβ4, and unresolved vendor products.
• Protocol 2: Maintenance / Chronic Use [Community/Biohacker/Anecdotal]; Route: Subcutaneous (SC) or Intramuscular (IM); Dose: Weekly Dose: 2.0 mg – 5.0 mg; Frequency: Once weekly; Duration: 8 to 12 weeks; Max: 5.0 mg (per week); Titration/loading: Biohacker loading: 5 mg/week (e.g., 2.5 mg Monday/Thursday) for first 4 weeks, then 2 mg/week for another 4 weeks.; Status: No - research, clinical trial, off-label, community/anecdotal, cosmetic, or otherwise not FDA-approved as written; Identity note: rows do not establish equivalence between TB-500 fragment, full-length Tβ4, and unresolved vendor products.
• Community protocols often use loading/maintenance-style cycles, but those are not trial-validated. The exact sequence and vial identity matter before comparing doses. Protocol rows are educational context, not personalized instructions, and product-label directions control when an approved product exists.

• Time until steady state: not calculable for generic TB-500 because product identity varies. Full-length Tβ4 pharmacokinetic data does not apply to the LKKTETQ fragment unless product, route, and formulation match.
• Half-life basis: no single validated human half-life applies to TB-500-family products. Full-length Tβ4, recombinant Tβ4, LKKTETQ fragment, N-acetylated fragments, and blends are different pharmacokinetic questions.
• Calculator rule: exclude generic TB-500/Tβ4-family products from steady-state, missed-dose, and loading-dose calculators unless exact human PK inputs are available for that specific product and route.
• Why this matters: weekly dosing patterns used online are driven more by community convention than by a validated plasma steady-state target.
• Different Tβ4-family identities can have different degradation, tissue distribution, and assay behavior. The calculator cannot assume one half-life or oxidation profile for all TB-500-labeled products. PK estimates are most useful for timing and accumulation awareness, not for proving efficacy or safety.

• BPC-157: common Wolverine pairing. Mechanistic framing is BPC-157 as vascular/fibroblast/gut-repair signal plus TB-500-family product as actin/cell-migration signal. The combination is popular but not proven superior in controlled human trials.
• GHK-Cu: common Glow add-on for skin, collagen, scar, and matrix remodeling. GHK-Cu does not automatically destroy TB-500/LKKTETQ, but stability is exact-formulation-specific.
• GLOW stack: BPC-157 + GHK-Cu + TB-500-family product. Always specify whether the third component is LKKTETQ fragment or full-length Tβ4.
• KPV: common Klow add-on when the target is gut, skin inflammation, autoimmune-type irritation, or mucosal inflammation.
• KLOW stack: GHK-Cu + BPC-157 + KPV + TB-500-family product. This is a market/community stack, not a standardized clinical product.
• Stacking caution: repair, angiogenesis, and product-identity uncertainty can increase theoretical cancer/angiogenesis concern and makes benefit/harm attribution difficult.
• Common stacks include BPC-157, GHK-Cu, KPV, and rehab protocols. Same-vial blend claims depend on whether the product is LKKTETQ fragment or full-length Tβ4 and on exact stability data. A sound stack accounts for both mechanism overlap and additive safety, tolerability, and interpretation risks.

• Product-identity risk: the biggest TB-500-specific safety issue is uncertainty about what is actually in the vial. A TB-500 label does not prove LKKTETQ fragment, full-length Tβ4, purity, sterility, endotoxin safety, dose accuracy, or stability.
• Residue/oxidation risk: TB-500/LKKTETQ lacks methionine/cysteine/tryptophan; Full-length Tβ4 contains methionine and behaves differently in copper/oxidation assessments.
• Immunogenicity and impurity risk: FDA highlights immunogenicity, aggregation, peptide-related impurities, API characterization, and lack of human exposure data for thymosin beta-4 fragment products.
• Reported side effects: community reports include lethargy, head pressure, transient flu-like sensations, injection-site reactions, water retention, unusual swelling, and sleep changes. True incidence is unknown.
• Contraindications/cautions: active malignancy, suspicious lesions, recent cancer treatment, proliferative retinopathy, severe cardiovascular disease, pregnancy, breastfeeding, active infection, and athlete testing status.
• Concerns include product misidentity, angiogenesis/fibrosis theoretical issues, immune response, injection risk, and lack of robust human safety data. Full-length and fragment risks do not merge blindly. The honest safety picture covers both known risks and uncertainty risks, especially where human data are limited.

• Injury tracking: Range of motion, pain score, strength testing, standardized photos for wounds, ultrasound/MRI for structural injuries, and return-to-training milestones.
• Safety tracking: Injection-site log, temperature/fever log, CBC/CMP when cycles are prolonged, and clinical evaluation for any unexplained swelling, shortness of breath, chest pain, severe headache, or signs of infection.
• Quality tracking: Record vendor, lot number, COA date, mass-spec result, purity, endotoxin value, reconstitution date, and storage conditions.
• Identity tracking: record whether the product is TB-500/LKKTETQ, full-length Tβ4, N-acetylated fragment, salt form, blend, or unknown; Record expected molecular mass and mass-spec result.
• Track injury diagnosis, pain/function, swelling, range of motion, rehab load, and adverse reactions. Avoid returning to training solely because pain improves. Useful monitoring matches the claimed goal, the most plausible risk, and objective baseline measures.

• FDA/compounding: FDA’s safety-risk page identifies thymosin beta-4 fragment LKKTETQ, also known as TB-500, and flags lack of human exposure data plus immunogenicity/aggregation/peptide-impurity concerns. FDA review does not equal approval.
• Full-length Tβ4 distinction: full-length thymosin beta-4/Tβ4 is a separate molecule from LKKTETQ TB-500 and is named separately in regulatory and evidence discussions.
• Anti-doping: WADA lists thymosin beta-4 and derivatives such as TB-500 as prohibited. Athletes should treat TB-500-family products as banned unless a qualified anti-doping professional confirms otherwise.
• Availability: mostly research-use-only vendors and nonstandard wellness channels. Product identity and sequence verification are critical.
• FDA describes TB-500 as thymosin beta-4 fragment LKKTETQ in safety-risk materials and has raised safety/characterization concerns. Full-length Tβ4 evidence does not confer approval on TB-500 products. Regulatory status spans distinct categories: FDA approval, ex-U.S. approval, investigational development, compounding review, supplement/cosmetic status, and RUO-market availability.

1. [D] Sosne et al. (2002). Thymosin beta 4 promotes corneal wound healing. Investigative Ophthalmology & Visual Science. PMID:11950239

2. [D] Sosne et al. (2007). Thymosin beta 4 suppression of corneal NF-kappaB: a potential antiinflammatory pathway. Experimental Eye Research. PMID:17254567.

3. [F] Sosne et al. (2009). Thymosin beta 4: a novel corneal wound healing and anti-inflammatory agent. Clinical Ophthalmology. PMID:19668473

4. [F] Sosne et al. (2010). Thymosin beta 4 and corneal wound healing. Annals of the New York Academy of Sciences. PMID:20536468

5. [F] Shrivastava et al. (2010). Thymosin beta 4 and cardiac repair. Annals of the New York Academy of Sciences. PMID:20536454

6. [F] Bollini et al. (2015). Thymosin beta 4: multiple functions in protection, repair and regeneration. Expert Opinion on Biological Therapy. PMID:26094634

7. [C] Zhang et al. (2025). Recombinant human thymosin beta 4 improves ischemic cardiac dysfunction in mice and patients with acute ST-segment elevation myocardial infarction after reperfusion. Cardiovascular Research, 121(17). PMID:41229390; DOI:10.1093/cvr/cvaf223.

8. [G] WADA. (2026). International Standard: Prohibited List. World Anti-Doping Agency.

9. [G] U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee.

10. [G] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks.

11. [G] World Anti-Doping Agency. The Prohibited List.

12. [D] Xing Y, et al. Progress on the Function and Application of Thymosin beta-4.

13. [C] Sosne G, et al. Thymosin beta-4 ophthalmic solution for dry eye and related corneal research.

14. [G] IVs in the Keys. Glow (BPC-157/TB-500/GHK-Cu).

15. [G] Bio Longevity Labs. KLOW Blend (GHK-Cu, BPC-157, TB-500, KPV).

16. [G] U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks. TB-500 described as thymosin beta-4 fragment LKKTETQ; safety-risk concerns include immunogenicity, aggregation, peptide impurities, and lack of human exposure data.

17. [D] Xing Y, et al. Progress on the Function and Application of Thymosin beta-4. Review context for full-length Tβ4 biology and 43-amino-acid peptide framing.

18. [D] Sosne G, et al. Biological activities of thymosin beta4 defined by active sites in short peptide sequences. PubMed PMID: 20179146. LKKTETQ active-region context.

19. [RouteEvidence] FDA. Certain bulk drug substances for use in compounding that may present significant safety risks.

20. [RouteEvidence] Sosne et al. Thymosin beta 4 ophthalmic solution for dry eye: randomized Phase II trial. PubMed.

21. [RouteEvidence] Treadwell et al. Thymosin beta 4 accelerates dermal healing in preclinical models and patients. PubMed.